A detailed history of Grandfield & Dodd, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Grandfield & Dodd, LLC holds 16,127 shares of BMRN stock, worth $1.36 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
16,127
Previous 15,872 1.61%
Holding current value
$1.36 Million
Previous $1.53 Million 7.97%
% of portfolio
0.09%
Previous 0.11%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 03, 2024

BUY
$83.81 - $99.0 $21,371 - $25,245
255 Added 1.61%
16,127 $1.41 Million
Q4 2023

Jan 31, 2024

BUY
$76.22 - $98.51 $16,692 - $21,573
219 Added 1.4%
15,872 $1.53 Million
Q3 2023

Oct 25, 2023

SELL
$85.07 - $94.48 $10,633 - $11,810
-125 Reduced 0.79%
15,653 $1.38 Million
Q2 2023

Aug 07, 2023

BUY
$86.68 - $100.3 $11,875 - $13,741
137 Added 0.88%
15,778 $1.37 Million
Q1 2023

Apr 28, 2023

BUY
$87.74 - $117.27 $20,267 - $27,089
231 Added 1.5%
15,641 $1.52 Million
Q4 2022

Jan 20, 2023

BUY
$80.93 - $108.63 $83,924 - $112,649
1,037 Added 7.21%
15,410 $0
Q3 2022

Nov 03, 2022

BUY
$82.16 - $96.94 $30,563 - $36,061
372 Added 2.66%
14,373 $1.22 Million
Q2 2022

Aug 01, 2022

BUY
$71.48 - $86.85 $5,361 - $6,513
75 Added 0.54%
14,001 $1.16 Million
Q1 2022

Apr 19, 2022

BUY
$74.28 - $92.69 $33,871 - $42,266
456 Added 3.39%
13,926 $1.07 Million
Q4 2021

Feb 08, 2022

BUY
$71.72 - $91.47 $95,889 - $122,295
1,337 Added 11.02%
13,470 $1.19 Million
Q3 2021

Oct 28, 2021

BUY
$74.77 - $85.47 $29,833 - $34,102
399 Added 3.4%
12,133 $940,000
Q2 2021

Jul 28, 2021

BUY
$75.51 - $84.79 $16,234 - $18,229
215 Added 1.87%
11,734 $980,000
Q1 2021

Apr 22, 2021

BUY
$74.73 - $90.69 $20,924 - $25,393
280 Added 2.49%
11,519 $870,000
Q4 2020

Jan 29, 2021

BUY
$72.61 - $90.2 $31,875 - $39,597
439 Added 4.06%
11,239 $990,000
Q3 2020

Nov 03, 2020

BUY
$71.87 - $131.03 $12,002 - $21,882
167 Added 1.57%
10,800 $820,000
Q2 2020

Jul 24, 2020

BUY
$79.55 - $124.22 $55,287 - $86,332
695 Added 6.99%
10,633 $1.31 Million
Q1 2020

May 14, 2020

BUY
$71.37 - $96.85 $37,469 - $50,846
525 Added 5.58%
9,938 $840,000
Q4 2019

Feb 07, 2020

BUY
$64.27 - $86.37 $61,056 - $82,051
950 Added 11.23%
9,413 $796,000
Q3 2019

Oct 30, 2019

BUY
$67.4 - $85.11 $62,682 - $79,152
930 Added 12.35%
8,463 $570,000
Q2 2019

Jul 29, 2019

BUY
$80.35 - $93.9 $53,432 - $62,443
665 Added 9.68%
7,533 $645,000
Q1 2019

Apr 26, 2019

BUY
$84.2 - $98.62 $9,430 - $11,045
112 Added 1.66%
6,868 $610,000
Q4 2018

Feb 12, 2019

BUY
$80.14 - $106.07 $7,533 - $9,970
94 Added 1.41%
6,756 $575,000
Q3 2018

Nov 02, 2018

BUY
$93.92 - $105.72 $6,574 - $7,400
70 Added 1.06%
6,662 $646,000
Q2 2018

Jul 27, 2018

BUY
$76.01 - $99.03 $3,420 - $4,456
45 Added 0.69%
6,592 $621,000
Q1 2018

May 04, 2018

SELL
$77.67 - $92.63 $18,640 - $22,231
-240 Reduced 3.54%
6,547 $531,000
Q4 2017

Feb 06, 2018

BUY
$80.76 - $95.13 $23,420 - $27,587
290 Added 4.46%
6,787 $605,000
Q3 2017

Nov 03, 2017

BUY
$80.6 - $94.95 $523,658 - $616,890
6,497
6,497 $605,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $15.6B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Grandfield & Dodd, LLC Portfolio

Follow Grandfield & Dodd, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grandfield & Dodd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Grandfield & Dodd, LLC with notifications on news.